Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
Background. Retinopathy of prematurity (ROP) is one of the common complications of prematurity. Intravitreal injection of ranibizumab (IVR), an antivascular endothelial growth factor (VEGF) drug, showed significant benefit for ROP. However, there are concerns about systemic complications of anti-VEG...
Saved in:
Main Authors: | Xuting Chen, Lin Zhou, Qi Zhang, Yu Xu, Peiquan Zhao, Hongping Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2019/2985161 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
by: Yu Xu, et al.
Published: (2016-01-01) -
Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs
by: Haitao Zhang, et al.
Published: (2022-01-01) -
Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
by: Enzhong Jin, et al.
Published: (2019-01-01) -
Bilateral Intravitreal Ranibizumab Injection and Panretinal Photocoagulation in a 16-Year-Old Girl with Severe Vaso-Occlusive Lupus Retinopathy
by: Hasan Can Doruk, et al.
Published: (2013-01-01) -
Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity
by: Chunling Huang, et al.
Published: (2025-01-01)